Table 4.
Adjusted Effectiveness Results* (Days to Discontinuation for Any Cause), by Antipsychotic Drug Treatment and Race-Ethnicity, 749 matched sets
| Racial-Ethnic Group |
N | Days to Discontinuation for Any Cause | |
|---|---|---|---|
| Median Days to Outcome |
95% CI | ||
| Clozapine | |||
| Blacks | 107 | 1422 | 961– 1840 |
| Latinos | 149 | 1659 | 1299 – 2052 |
| Whites | 493 | 1228 | 1070 – 1593 |
| Other Antipsychotics | |||
| Blacks | 214 | 459 | 364 – 694 |
| Latinos | 298 | 566 | 426 – 754 |
| Whites | 986 | 639 | 584 – 701 |
| Overall (All Antipsychotics Combined) | |||
| Blacks | 321 | 720 | 569 – 937 |
| Latinos | 447 | 895 | 754 – 1038 |
| Whites | 1479 | 812 | 742 – 883 |
*
Adjusted through matching by age, sex, inpatient days for schizophrenia, four measures of comorbidity (psychiatric, substance use disorder, metabolic, and other medical comorbidity), SSI status, geographic area, and quarter; estimates generated by the model without interaction terms.